SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Pancreas - Pancreatic Cancers - VIPoma Written by Dr Sebastian Zeki
Knowledge


Knows the presentation investigation and staging of pancreatic
cancer

Recognises the importance of considering and being able to identify
uncommon pancreatic tumours (such as neuroendocrine or
intrapapillary mucinous tuours)

Knows the range of potential therapies and recognises the factors
that make such tumours potentially operable or inoperable

Knows the prevalence and natural history of benign cysts/serous
cystadenoma and potentially malignant cystic lesions

Knows the options for palliative treatment
Skills
Shows ability to sequence investigations appropriately
Understands value of multi-disciplinary team
Recognises the importance of considering possibility that the tumour
is unusual

Behaviours
Communicates effectively within the multi-disciplinary team and with
the patient and their family

VIPoma

>3cm diameter Luminal epithelium Inc cAMP productionNet fluid secretion into lumen VIPoma Diagnosis[Serum VIP] > 75 pg/mL (measured by radioimmu-noassay.) ; repeat if elevated. CT/ Octreotide scan/ EUS can help locate the lesion. VIP SYndrome (pancreatic cholera syndrome, Verner-Morrison syndrome)=watery diarrhea, hypokalemia, and hypochlorhydria or achlorhydria (WDHA) syndrome20% get facial flushing VIP secreted Lesion characteristicsLesions are solitaryThey are usually >3cm .They are usually in the tail.They usually have metastasized by dx.They can occur outside the pancreas. Prognosis The 5 year survival is 88%. Incidence of 1/10,000,000 Written by Dr Sebastian Zeki

Related Stories

Transcriptomic landscape of transposable elements reveals LTR7-PLAAT4 as a potential oncogene and therapeutic target in pancreatic adenocarcinoma

Radiopathomics Signature for Prognosis and Prediction of Chemotherapy Benefit in Unresectable Pancreatic Cancer

Graphene Quantum Dots in Cancer Diagnostics and Therapeutics: Advances in Biosensing, Imaging, and Treatment Applications

Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target

A novel pan class-I glucose transporter inhibitor DRB18 exhibits synergistic effects with paclitaxel in vitro and in vivo against human non-small cell lung cancer